Scarica l'app Stockscreener
40.78
3.02%
-1.27
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$42.05
Aprire:
$42.09
Volume 24 ore:
527.38K
Relative Volume:
0.86
Capitalizzazione di mercato:
$740.21M
Reddito:
$116.88M
Utile/perdita netta:
$-25.09M
Rapporto P/E:
-291.29
EPS:
-0.14
Flusso di cassa netto:
$-20.74M
1 W Prestazione:
-16.64%
1M Prestazione:
+2.10%
6M Prestazione:
+91.46%
1 anno Prestazione:
+114.52%
Intervallo 1D:
$40.52
$42.26
Intervallo di 1 settimana:
$39.60
$48.00
Portata 52W:
$14.63
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Nome
Rigel Pharmaceuticals
Settore
Industria
Telefono
650-624-1100
Indirizzo
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Confronta RIGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
40.78 | 763.26M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-04-03 | Ripresa | Piper Sandler | Neutral |
| 2022-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-08 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Iniziato | B. Riley Securities | Neutral |
| 2020-11-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Ripresa | JP Morgan | Overweight |
| 2019-03-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Iniziato | Citigroup | Buy |
| 2018-05-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Ripresa | Piper Jaffray | Overweight |
| 2017-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Ripresa | H.C. Wainwright | Buy |
| 2017-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-31 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Reiterato | Piper Jaffray | Overweight |
| 2016-07-13 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-13 | Iniziato | Piper Jaffray | Overweight |
| 2016-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Reiterato | Stifel | Buy |
| 2012-11-29 | Iniziato | UBS | Neutral |
| 2012-11-06 | Reiterato | Oppenheimer | Outperform |
| 2012-03-26 | Iniziato | Canaccord Genuity | Hold |
| 2010-12-10 | Downgrade | MP Advisors | Outperform → Market Perform |
Mostra tutto
Rigel Pharmaceuticals Borsa (RIGL) Ultime notizie
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Insiders Who Sold Rigel Pharmaceuticals Made The Right Call As Market Cap Slides By US$97m - simplywall.st
Rigel Pharmaceuticals reports promising Phase 1b study results - MSN
Armistice Capital LLC Acquires 84,000 Shares of Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Top-Rated Stocks: Rigel Pharmaceuticals Sees Composite Rating Climb To 96 - MSN
Rigel Pharmaceuticals Reports Promising Phase 1b Study Results - TipRanks
Rigel Pharmaceuticals Inc Presents Updated Data from Phase 1b Study on R289 - TradingView
With EPS Growth And More, Rigel Pharmaceuticals (NASDAQ:RIGL) Makes An Interesting Case - 富途牛牛
Rigel Pharmaceuticals Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading Down 13.7%Should You Sell? - MarketBeat
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals (RIGL) Shares Promising Data from Phase 1b Study - GuruFocus
Rigel Pharmaceuticals announces updated data from Phase 1b study of R2891 - TipRanks
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition - Lelezard
How the Narrative Surrounding Rigel Pharmaceuticals Is Shifting After Upgraded Targets and Guidance - Yahoo Finance
Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy? - sharewise.com
Why Rigel Pharmaceuticals Inc. (RI2) stock could break out in 2025July 2025 Analyst Calls & Daily Profit Maximizing Trade Tips - Newser
Is Rigel Pharmaceuticals Inc. (RI2) stock supported by free cash flowTrade Analysis Report & Long-Term Safe Return Strategies - Newser
Will Rigel Pharmaceuticals Inc. (RI2) stock split increase liquidityWeekly Trade Review & Free High Accuracy Swing Entry Alerts - Newser
Why pension funds invest in Rigel Pharmaceuticals Inc. (RI2) stock2025 Year in Review & Verified Stock Trade Ideas - Newser
Will Rigel Pharmaceuticals Inc. (RI2) stock enhance shareholder valueMarket Sentiment Report & AI Based Trade Execution Alerts - Newser
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock? - sharewise.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading Down 6.1%Time to Sell? - MarketBeat
Will Rigel Pharmaceuticals Inc. (RI2) stock outperform small cap peers2025 Market Overview & Weekly High Potential Stock Alerts - Newser
(RIGL) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Would You Still Hold Rigel Pharmaceuticals Stock If It Fell Another 30%? - Trefis
Is Rigel Pharmaceuticals Inc. (RI2) stock a top dividend aristocrat candidatePortfolio Performance Report & Long-Term Investment Growth Plans - Newser
Is Rigel Pharmaceuticals Inc. (RI2) stock a buy before new product rolloutWeekly Market Summary & Stock Market Timing Techniques - Newser
Rigel Pharmaceuticals (RIGL) Stock Analysis Report | Financials & Insights - Benzinga
Can Rigel Pharmaceuticals Inc. (RI2) stock ride next bull market cycleTake Profit & Long-Term Capital Growth Strategies - Newser
Is Rigel Pharmaceuticals Inc. stock a buy for dividend growthMarket Performance Summary & Verified Technical Signals - Newser
All You Need to Know About Rigel (RIGL) Rating Upgrade to Strong Buy - MSN
What analysts say about Rigel Pharmaceuticals Inc RI2 stockVolume Analysis Techniques & Accelerated Financial Growth - earlytimes.in
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference - Eastern Progress
Is Rigel Pharmaceuticals Inc. stock near bottom after decline2025 Technical Overview & Low Risk Profit Maximizing Plans - moha.gov.vn
Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue? - sharewise.com
Rigel Pharmaceuticals Inc RI2 Stock Analysis and ForecastSmall Cap Stock Opportunities & Discover Your Financial Freedom Formula - earlytimes.in
If EPS Growth Is Important To You, Rigel Pharmaceuticals (NASDAQ:RIGL) Presents An Opportunity - simplywall.st
Dynamic Technology Lab Private Ltd Sells 13,113 Shares of Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals (RIGL) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Rigel Pharma: Q3 Earnings Showcase Robust Growth (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals: Behind The Huge Rally (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Institutional Investors Control 85% of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) and Were Rewarded Last Week After Stock Increased 10% - 富途牛牛
Rigel Stock Surges on Upward Earnings Revisions - Ad-hoc-news.de
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Price Is Right But Growth Is Lacking After Shares Rocket 54% - 富途牛牛
How Recent Developments Are Rewriting the Story for Rigel Pharmaceuticals - Yahoo Finance
Rigel Pharmaceuticals, Inc.Common Stock (Nasdaq:RIGL) Stock Quote - Markets Financial Content
RIGLRigel Pharmaceuticals Stock Price and Quote - Finviz
How Rigel Pharmaceuticals Inc. (RI2) stock stacks up against competitorsJuly 2025 Analyst Calls & Safe Capital Allocation Plans - newser.com
How Rigel Pharmaceuticals Inc. (RI2) stock benefits from digital adoptionOptions Play & Daily Profit Focused Stock Screening - newser.com
Rigel Pharmaceuticals Azioni (RIGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rigel Pharmaceuticals Azioni (RIGL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,734 |
38,020 |
57,235 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 04 '25 |
Sale |
20.92 |
2,125 |
44,457 |
53,500 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,796 |
39,379 |
51,704 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 04 '25 |
Sale |
20.92 |
4,952 |
103,601 |
243,854 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '25 |
Sale |
21.93 |
4,400 |
96,474 |
239,454 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 04 '25 |
Sale |
20.92 |
1,448 |
30,294 |
40,169 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 05 '25 |
Sale |
21.93 |
1,339 |
29,359 |
38,830 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):